Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab + Nivolumab in Gastric/GEJ Adenocarcinoma
NCT02864381Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of andecaliximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Gilead Sciences. Started Sep 2016; status: completed.
02
Drugs
andecaliximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02864381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864381.